Document is current

Article History

Received: 25 March 2018

Accepted: 21 June 2018

First Online: 20 July 2018

Ethics approval and consent to participate

: Establishment of PDX models from NSCLC patients was approved (EA3/001/06) by the local ethical review committee (Charité Berlin). Written informed consent to participate in the study was obtained from all patients. The research conformed with the principles of the Declaration of Helsinki. The use of clinical data and patient’s material was approved by the institutional review board of the ELK Berlin Chest Hospital. All mice used in the study were handled in accordance with the Guidelines for the Welfare and Use of Animals in Cancer Research []. Their use was approved by the local responsible authorities (approval no. G 0030/15), according to the German Animal Protection Law.

: Not applicable.

: Hans Lehrach is a chairman of and Felix Dreher is employed at Alacris Theranostics GmbH Berlin, Germany. Jana Rolff, Michael Becker, and Iduna Fichtner are employed by the Experimental Pharmacology and Oncology Berlin-Buch GmbH, Germany. The remaining authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.